Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis

被引:75
作者
Dimopoulos, Meletios A. [1 ]
Roussou, Maria [1 ]
Gavriatopoulou, Maria [1 ]
Psimenou, Erasmia [1 ]
Eleutherakis-Papaiakovou, Evangelos [1 ]
Migkou, Magdalini [1 ]
Matsouka, Charis [1 ]
Mparmparousi, Despoina [1 ]
Gika, Dimitra [1 ]
Kafantari, Eftychia [1 ]
Ziogas, Dimitrios [1 ]
Fotiou, Despoina [1 ]
Panagiotidis, Ioannis [1 ]
Terpos, Evangelos [1 ]
Kastritis, Efstathios [1 ]
机构
[1] Univ Athens, Sch Med, Dept Clin Therapeut, 80 Vas Sofias Ave, Athens 11528, Greece
关键词
ORAL PROTEASOME INHIBITOR; REFRACTORY MULTIPLE-MYELOMA; DEXAMETHASONE; LENALIDOMIDE; IMPAIRMENT; IXAZOMIB; SAFETY; PHASE-1; REVERSIBILITY; POMALIDOMIDE;
D O I
10.1002/ajh.24335
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Renal failure (RF) is a common and severe complication of symptomatic myeloma, associated with significant morbidity and mortality. Such patients are commonly excluded from clinical trials. Bortezomib/dexamethasone (VD)-based regimens are the backbone of the treatment of newly diagnosed MM patients who present with severe RF even those requiring dialysis. We analyzed the outcomes of 83 consecutive bortezomib-treated patients with severe RF (eGFR<30 ml/min/1.73 m(2)), of which 31 (37%) required dialysis. By IMWG renal response criteria, 54 (65%) patients achieved at least MRrenal, including CRrenal in 35% and PRrenal in 12%. Triplet combinations (i.e., VD plus a third agent) versus VD alone were associated with higher rates of renal responses (72 vs. 50%; P=0.06). Fifteen of the 31 (48%) patients became dialysis independent within a median of 217 days (range 11-724). Triplets were associated with a higher probability of dialysis discontinuation (57 vs. 35%). Serum free light chain (sFLC) level 11,550 mg/L was associated with lower rates of major renal response, longer time to major renal response, lower probability, and longer time to dialysis discontinuation. Rapid myeloma response (PR within the first month) was also associated with higher rates of renal response. Patients who became dialysis-independent had longer survival than those remaining on dialysis. In conclusion, VD-based triplets are associated with a significant probability of renal response and dialysis discontinuation, improving the survival of patients who became dialysis independent. Rapid disease response is important for renal recovery and sFLCs are predictive of the probability and of the time required for renal response. Am. J. Hematol. 91:499-502, 2016. (c) 2016 Wiley Periodicals, Inc.
引用
收藏
页码:499 / 502
页数:4
相关论文
共 32 条
[1]   Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party [J].
Augustson, BM ;
Begum, G ;
Dunn, JA ;
Barth, NJ ;
Davies, F ;
Morgan, G ;
Behrens, J ;
Smith, A ;
Child, JA ;
Drayson, MT .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9219-9226
[2]   Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety [J].
Badros, A. Z. ;
Vij, R. ;
Martin, T. ;
Zonder, J. A. ;
Kunkel, L. ;
Wang, Z. ;
Lee, S. ;
Wong, A. F. ;
Niesvizky, R. .
LEUKEMIA, 2013, 27 (08) :1707-1714
[3]   Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study [J].
Chanan-Khan, Asher A. ;
Kaufman, Jonathan L. ;
Mehta, Jayesh ;
Richardson, Paul G. ;
Miller, Kena C. ;
Lonial, Sagar ;
Munshi, Nikhil C. ;
Schlossman, Robert ;
Tariman, Joseph ;
Singhal, Seema .
BLOOD, 2007, 109 (06) :2604-2606
[4]   Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study [J].
de la Rubia, Javier ;
Roig, Monica ;
Ibanez, Angela ;
Garcia, Inmaculada ;
Vera, Jose A. ;
Aguilar, Carlos ;
del Campo, Raquel ;
Gonzalez, Nicolas ;
Martinez, Rafael ;
Palomera, Luis ;
Picon, Isabel ;
Rodriguez, Juan N. ;
Sanz, Miguel A. .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 85 (04) :363-365
[5]   Pathogenesis and treatment of renal failure in multiple myeloma [J].
Dimopoulos, M. A. ;
Kastritis, E. ;
Rosinol, L. ;
Blade, J. ;
Ludwig, H. .
LEUKEMIA, 2008, 22 (08) :1485-1493
[6]   Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors [J].
Dimopoulos, M. A. ;
Sonneveld, P. ;
Siegel, D. ;
Palumbo, A. ;
San-Miguel, J. .
ANNALS OF ONCOLOGY, 2015, 26 (11) :2247-2256
[7]   Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma [J].
Dimopoulos, M. A. ;
Leleu, X. ;
Palumbo, A. ;
Moreau, P. ;
Delforge, M. ;
Cavo, M. ;
Ludwig, H. ;
Morgan, G. J. ;
Davies, F. E. ;
Sonneveld, P. ;
Schey, S. A. ;
Zweegman, S. ;
Hansson, M. ;
Weisel, K. ;
Mateos, M. V. ;
Facon, T. ;
Miguel, J. F. S. .
LEUKEMIA, 2014, 28 (08) :1573-1585
[8]   The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma [J].
Dimopoulos, M. A. ;
Roussou, M. ;
Gkotzamanidou, M. ;
Nikitas, N. ;
Psimenou, E. ;
Mparmparoussi, D. ;
Matsouka, C. ;
Spyropoulou-Vlachou, M. ;
Terpos, E. ;
Kastritis, E. .
LEUKEMIA, 2013, 27 (02) :423-429
[9]  
Dimopoulos MA, 2015, HAEMATOLOGICA
[10]   The Efficacy and Safety of Lenalidomide Plus Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients With Impaired Renal Function [J].
Dimopoulos, Meletios ;
Alegre, Adrian ;
Stadtmauer, Edward A. ;
Goldschmidt, Hartmut ;
Zonder, Jeffrey A. ;
de Castro, Carlos M. ;
Masliak, Zvenyslava ;
Reece, Donna ;
Olesnyckyj, Marta ;
Yu, Zhinuan ;
Weber, Donna M. .
CANCER, 2010, 116 (16) :3807-3814